TCM
TEVA icon

Tributary Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Tributary Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-55,200
Closed -$2.16M – 235
2013
Q2 		$2.16M Buy
+55,200
New +$2.15M 0.35% 140

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Tributary Capital Management's TEVA Position: Q3 2013 in Review

Tributary Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2013, closing a stake of 55,200 shares — an estimated $2.16M sold.

Tributary Capital Management first reported a position in TEVA in Q2 2013 and held it in 1 quarter. The position peaked at $2.16M in Q2 2013. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

  • Tributary Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Tributary Capital Management sold 55,200 Teva Pharmaceuticals shares in Q3 2013, an estimated $2.16M.
  • Tributary Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Tributary Capital Management's Teva Pharmaceuticals position peaked at $2.16M in Q2 2013.
  • 705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on Tributary Capital Management's 13F filing for Q3 2013, filed 8 Nov 2013.